Hui Feng

Title: Innovations by Hui Feng in Cancer Treatment

Introduction

Hui Feng is an accomplished inventor based in Potomac, MD (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins for cancer treatment. His innovative work has led to the creation of a unique fusion protein that holds promise for advancing cancer therapies.

Latest Patents

Hui Feng holds a patent for "OX40L fusion proteins and uses thereof." This patent describes OX40L huIgG4 fusion polypeptide subunits that comprise a human IgG4 Fc domain, a trimerization domain, and the receptor binding domain of Ox40 ligand. The fusion polypeptide subunits can self-assemble into hexameric proteins, which are crucial for their therapeutic applications. The patent also outlines methods for making these fusion polypeptide subunits and hexameric proteins, as well as their potential uses in cancer treatment.

Career Highlights

Hui Feng is currently associated with MedImmune Limited, a leading biotechnology company. His work at MedImmune has focused on developing innovative solutions to combat cancer through advanced protein engineering. His expertise in this area has positioned him as a key contributor to the company's research and development efforts.

Collaborations

Hui Feng has collaborated with notable colleagues, including Melissa Marie Damschroder and Michael Oberst. These collaborations have fostered a productive research environment, enabling the team to explore new avenues in cancer treatment.

Conclusion

Hui Feng's innovative work in the development of OX40L fusion proteins represents a significant advancement in cancer therapy. His contributions to MedImmune Limited and collaborations with fellow researchers highlight his commitment to improving treatment options for patients. The impact of his inventions is poised to make a lasting difference in the field of biotechnology.